[1]ChemicalPapers,2014,vol.68,p.1408-1414
[2]JournaloftheAmericanChemicalSociety,2016,vol.138,p.8470-8475
[3]Patent:CN103910672,2016,B
[4]Patent:CN103910672,2016,B
[5]JournalofOrganicChemistry,2017,vol.82,p.8716-8724
[1]ChemicalPapers,2014,vol.68,p.1408-1414
[2]JournaloftheAmericanChemicalSociety,2016,vol.138,p.8470-8475
[3]Patent:CN103910671,2016,B
[4]Patent:CN103910671,2016,B
[5]OrganicProcessResearchandDevelopment,2016,vol.20,p.1509-1519
[6]OrganicProcessResearchandDevelopment,2016,vol.20,p.1509-1519
[7]JournalofOrganicChemistry,2017,vol.82,p.8716-8724
[8]Patent:CN106866507,2017,A
[9]Patent:US2018/273477,2018,A1
[10]AngewandteChemie-InternationalEdition,2019,vol.58,p.13499-13506 Angew.Chem.,2019,vol.131,p.13633-13640,8
[1]CurrentPatentAssignee:TIANJINUNIVERSITY-CN104926714,2017,BLocationinpatent:Paragraph0041-0043
[2]CurrentPatentAssignee:NANJINGTIANYUEXINGBIOTECH-CN109456255,2019,ALocationinpatent:Paragraph0037;0038;0039;0040
[3]CurrentPatentAssignee:XINFAPHARMACEUTICALCOLTD-CN111056994,2020,ALocationinpatent:Paragraph0083-0084;0093-0094
[4]CurrentPatentAssignee:XINFAPHARMACEUTICALCOLTD-CN107200708,2017,ALocationinpatent:Paragraph0089;0090;0091;0092;0093
[5]CurrentPatentAssignee:SINOBIOPHARMACEUTICALLIMITED;SOUTHEASTPHARMACEUTICALSCOLTD-CN103910671,2016,BLocationinpatent:Paragraph0133;0134;0135
[6]CurrentPatentAssignee:SOUTHEASTPHARMACEUTICALSCOLTD;SINOBIOPHARMACEUTICALLIMITED-CN103910672,2016,BLocationinpatent:Paragraph0183-0185;0191-0193
[7]Cao,Meng;Hu,Hua-You;Zhao,Hu-Cheng;Zhang,Xi-Quan;Gu,Hong-Mei;Yang,Ling;Cai,Jin;Wang,Peng;Hu,Bing;Ji,Min[ChemicalPapers,2014,vol.68,#10,p.1408-1414]
[8]CurrentPatentAssignee:AZADPHARMAAG-US2018/273477,2018,A1Locationinpatent:Paragraph0031;0045;0046;0047;0051
[9]Yu,Qingzhen;Hu,Le'An;Wang,Yue;Zheng,Shasha;Huang,Jianhui[AngewandteChemie-InternationalEdition,2015,vol.54,#50,p.15284-15288][Angew.Chem.,2015,vol.127,#50,p.15499-15503,5]
[10]Angelaud,Remy;Reynolds,Mark;Venkatramani,Cadapakam;Savage,Scott;Trafelet,Huldreich;Landmesser,Thomas;Demel,Peter;Levis,Michael;Ruha,Olivier;Rueckert,Baerbel;Jaeggi,Heinz[OrganicProcessResearchandDevelopment,2016,vol.20,#8,p.1509-1519]
[1]Cao,Meng;Hu,Hua-You;Zhao,Hu-Cheng;Zhang,Xi-Quan;Gu,Hong-Mei;Yang,Ling;Cai,Jin;Wang,Peng;Hu,Bing;Ji,Min[ChemicalPapers,2014,vol.68,#10,p.1408-1414]
[2]CurrentPatentAssignee:SINOBIOPHARMACEUTICALLIMITED;SOUTHEASTPHARMACEUTICALSCOLTD-CN103910671,2016,B
[3]CurrentPatentAssignee:SINOBIOPHARMACEUTICALLIMITED;SOUTHEASTPHARMACEUTICALSCOLTD-CN103910671,2016,B
[4]CurrentPatentAssignee:SINOBIOPHARMACEUTICALLIMITED;SOUTHEASTPHARMACEUTICALSCOLTD-CN103910671,2016,B
[5]CurrentPatentAssignee:SINOBIOPHARMACEUTICALLIMITED;SOUTHEASTPHARMACEUTICALSCOLTD-CN103910671,2016,B
[6]CurrentPatentAssignee:SOUTHEASTPHARMACEUTICALSCOLTD;SINOBIOPHARMACEUTICALLIMITED-CN103910672,2016,B
[7]CurrentPatentAssignee:SOUTHEASTPHARMACEUTICALSCOLTD;SINOBIOPHARMACEUTICALLIMITED-CN103910672,2016,B
[8]CurrentPatentAssignee:AZADPHARMAAG-US2018/273477,2018,A1
[1]Cao,Meng;Hu,Hua-You;Zhao,Hu-Cheng;Zhang,Xi-Quan;Gu,Hong-Mei;Yang,Ling;Cai,Jin;Wang,Peng;Hu,Bing;Ji,Min[ChemicalPapers,2014,vol.68,#10,p.1408-1414]
[2]CurrentPatentAssignee:SOUTHEASTPHARMACEUTICALSCOLTD;SINOBIOPHARMACEUTICALLIMITED-CN103910672,2016,B
[3]CurrentPatentAssignee:SOUTHEASTPHARMACEUTICALSCOLTD;SINOBIOPHARMACEUTICALLIMITED-CN103910672,2016,B
Title: Gli2 gene-environment interactions contribute to the etiological complexity of holoprosencephaly: evidence from a mouse model.
Journal: Disease models & mechanisms 20161101
Title: Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications.
Journal: Dermatology and therapy 20150601
Title: The Hedgehog pathway: role in cell differentiation, polarity and proliferation.
Journal: Archives of toxicology 20150201
Title: Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition.
Journal: Nature medicine 20140701
Title: Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
Journal: The Journal of thoracic and cardiovascular surgery 20140101
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: The dawn of hedgehog inhibitors: Vismodegib.
Journal: Journal of pharmacology & pharmacotherapeutics 20130101
Title: Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.
Journal: Bioorganic & medicinal chemistry 20121115
Title: Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells.
Journal: Stem cells and development 20121101
Title: Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
Journal: Cancer research 20121001
Title: Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Journal: Clinical therapeutics 20121001
Title: In vitro and in vivo characterization of a novel Hedgehog signaling antagonist in human glioblastoma cell lines.
Journal: International journal of cancer 20120715
Title: Effects of the Hedgehog pathway inhibitor GDC-0449 on lung cancer cell lines are mediated by side populations.
Journal: Clinical and experimental medicine 20120301
Title: Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity.
Journal: Journal of medicinal chemistry 20120223
Title: Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.
Journal: ACS medicinal chemistry letters 20120209
Title: The hedgehog pathway inhibitor GDC-0449 alters intracellular Ca2+ homeostasis and inhibits cell growth in cisplatin-resistant lung cancer cells.
Journal: Anticancer research 20120101
Title: Ivacaftor, vismodegib, and ingenol mebutate.
Journal: Journal of the American Pharmacists Association : JAPhA 20120101
Title: Emerging treatments and signaling pathway inhibitors.
Journal: Seminars in cutaneous medicine and surgery 20111201
Title: Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication.
Journal: Hepatology (Baltimore, Md.) 20111101
Title: A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20110801
Title: Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.
Journal: Cancer research 20110801
Title: Absorption, distribution, metabolism, and excretion of [¹⁴C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20110601
Title: AACR highlights: promise for treating pancreatic cancer.
Journal: Journal of the National Cancer Institute 20110518
Title: Hedgehog signaling and therapeutics in pancreatic cancer.
Journal: Carcinogenesis 20110401
Title: New agents for prevention of ultraviolet-induced nonmelanoma skin cancer.
Journal: Seminars in cutaneous medicine and surgery 20110301
Title: The role of targeted molecular inhibitors in the management of advanced nonmelanoma skin cancer.
Journal: Seminars in cutaneous medicine and surgery 20110301
Title: Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
Journal: Cancer research 20110115
Title: Up-regulation of sonic hedgehog contributes to TGF-β1-induced epithelial to mesenchymal transition in NSCLC cells.
Journal: PloS one 20110101
Title: Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer.
Journal: PloS one 20110101
Title: Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms.
Journal: PloS one 20110101
Title: Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway.
Journal: Bioorganic & medicinal chemistry letters 20101115
Title: Modulators of the hedgehog signaling pathway.
Journal: Bioorganic & medicinal chemistry 20100915
Title: Interplay of dissolution, solubility, and nonsink permeation determines the oral absorption of the Hedgehog pathway inhibitor GDC-0449 in dogs: an investigation using preclinical studies and physiologically based pharmacokinetic modeling.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20100701
Title: Small-molecule modulators of the Sonic Hedgehog signaling pathway.
Journal: Molecular bioSystems 20100101
Title: Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20091101
Title: Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
Journal: Science (New York, N.Y.) 20091023
Title: GDC-0449-a potent inhibitor of the hedgehog pathway.
Journal: Bioorganic & medicinal chemistry letters 20091001
Title: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
Journal: The New England journal of medicine 20090917
Title: Evidence for allosteric interactions of antagonist binding to the smoothened receptor.
Journal: The Journal of pharmacology and experimental therapeutics 20090601
Title: Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.
Journal: Neoplasia (New York, N.Y.) 20090101
Title: Scales SJ, et al. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci. 2009, 30(6), 303-312.
Title: Zhang Y, et al. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia. 2009, 11(1), 96-101.
Title: Tian F, et al. The hedgehog pathway inhibitor GDC-0449 alters intracellular Ca2+ homeostasis and inhibits cell growth in NSC 119875-resistant lung cancer cells. Anticancer Res. 2012, 32(1), 89-94.
Title: Wong H, et al. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Clin Cancer Res. 2011, 17(14), 4682-4692.
Title: Elhenawy AA, et al. Possible antifibrotic effect of GDC-0449 (Vismodegib), a hedgehog-pathway inhibitor, in mice model of Schistosoma-induced liver fibrosis. Parasitol Int. 2017 Oct;66(5):545-554.
Title: Ma W, et al. Reduced Smoothened level rescued Aβ-induced memory deficits and neuronal inflammation in animal models of Alzheimer's disease. J Genet Genomics. 2018 May 20;45(5):237-246.
